Payment overview · 2025
General Payments
$538.26
22 reported records · 9 companies
Healthcare provider profile · identity verified
Timothy Scott Huff
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · OLIVE HILL, KY · NPI 1205214426
Verified facts
What the public records show
CMS Open Payments records show Timothy Scott Huff received $538.26 in general payments during 2025 across 22 reported records.
AstraZeneca Pharmaceuticals LP accounted for 32.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $172.10 | 32.0% | 7 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $118.81 | 22.1% | 4 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $68.73 | 12.8% | 2 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $59.95 | 11.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.18 | 9.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $19.65 | 3.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $16.89 | 3.1% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $16.67 | 3.1% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $14.28 | 2.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $538.26 | 22 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $128.68 | 4 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $118.81 | 4 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $112.32 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $54.54 | 1 | 2025 |
Source payment records
|
|||||
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $54.54 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.18 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.18 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $42.47 | 2 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $22.58 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $19.65 | 1 | 2025 |
Source payment records
|
|||||
| BEVESPI AEROSPHERE Normalized: bevespi aerosphere |
Drug | AstraZeneca Pharmaceuticals LP | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $16.67 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $14.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
68 | 11 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
39 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 305 | 98 |
| Omeprazole | Omeprazole | 284 | 91 |
| Atorvastatin Calcium | Atorvastatin Calcium | 240 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 235 | 75 |
| Prednisone | Prednisone | 205 | 150 |
| Montelukast Sodium | Montelukast Sodium | 200 | 61 |
| Metformin Hcl | Metformin Hcl | 178 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 147 | 55 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 143 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 140 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 134 | 40 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 41 |
| Simvastatin | Simvastatin | 124 | 33 |
| Gabapentin | Gabapentin | 123 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 113 | 42 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 102 | 37 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 97 | 77 |
| Azithromycin | Azithromycin | 96 | 83 |
| Ibuprofen | Ibuprofen | 93 | 35 |
| Furosemide | Furosemide | 92 | 37 |
| Metoprolol Succinate | Metoprolol Succinate | 87 | 29 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 85 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 82 | 42 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 80 | 18 |
| Potassium Chloride | Potassium Chloride | 79 | 28 |
| Losartan Potassium | Losartan Potassium | 78 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 25 |
| Meloxicam | Meloxicam | 74 | 24 |
| Januvia | Sitagliptin Phosphate | 70 | 20 |
| Sertraline Hcl | Sertraline Hcl | 69 | 22 |
| Ozempic | Semaglutide | 68 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 59 | 26 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Carvedilol | Carvedilol | 57 | 20 |
| Alprazolam | Alprazolam | 55 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 55 | 13 |
| Metformin Hcl Er | Metformin Hcl | 53 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 52 | 16 |
| Diclofenac Sodium | Diclofenac Sodium | 51 | 18 |
| Tamsulosin Hcl | Tamsulosin Hcl | 49 | 17 |
| Trazodone Hcl | Trazodone Hcl | 48 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 47 | 11 |
| Alendronate Sodium | Alendronate Sodium | 46 | 15 |
| Fenofibrate | Fenofibrate | 43 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 42 | 15 |
| Methocarbamol | Methocarbamol | 42 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 42 | 12 |
| Buspirone Hcl | Buspirone Hcl | 41 | 12 |
| Warfarin Sodium | Warfarin Sodium | 41 | 11 |
| Diazepam | Diazepam | 40 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 40 | 11 |
| Naproxen | Naproxen | 40 | 16 |
| Eliquis | Apixaban | 39 | 13 |
| Glipizide Er | Glipizide | 39 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 33 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 38 | 14 |
| Ondansetron Odt | Ondansetron | 38 | 26 |
| Ventolin Hfa | Albuterol Sulfate | 35 | 14 |
| Allopurinol | Allopurinol | 33 | 11 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 12 |
| Trulicity | Dulaglutide | 32 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 30 | suppressed |
| Famotidine | Famotidine | 30 | 11 |
| Glipizide | Glipizide | 30 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 30 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 29 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 26 |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | 12 |
| Jardiance | Empagliflozin | 24 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 22 | suppressed |
| Glimepiride | Glimepiride | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 19 | 17 |
| Glyburide | Glyburide | 19 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 19 | suppressed |
| Colchicine | Colchicine | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 13 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Cephalexin | Cephalexin | 15 | 15 |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Topiramate | Topiramate | 15 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 15 | suppressed |
| Atenolol | Atenolol | 14 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Ezetimibe | Ezetimibe | 14 | suppressed |
| Ketoconazole | Ketoconazole | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 13 | suppressed |
| Mounjaro | Tirzepatide | 13 | suppressed |
| Synthroid | Levothyroxine Sodium | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Bumetanide | Bumetanide | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | 11 |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $538.26 · 22 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BEVESPI AEROSPHERE, BREZTRI, Cologuard Collection Kit, DUPIXENT, FANAPT, FARXIGA, FASENRA, HETLIOZ, JARDIANCE, NURTEC ODT, Ozempic, Rybelsus, XIFAXAN | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error